Trial · NCT07342439
Study of Serine Supplementation to Protect Vision in MacTel
NCT07342439, Phase 3, Not yet recruiting, The Lowy Medical Research Institute Limited
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Serine Supplementation to Protect Vision in MacTel. Trials, record NCT07342439. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07342439
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Serine Supplementation to Protect Vision in MacTel
- NCT number
- NCT07342439
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 120 participants, estimated
- Lead sponsor
- The Lowy Medical Research Institute Limited
- Conditions
- Macular Telangiectasia Type 2 (MacTel)
- Interventions
- L-serine, Placebo
- First posted
- 2026-01-15
- Last updated
- 2026-01-15
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | EZ loss | Baseline through Month 24 | Mean rate of change in the total area of EZ loss (IS/OS; macular photoreceptor loss) from Baseline (BL) through Month 24 (M24), as assessed using SD-OCT in the study eye(s). |
| Secondary | EZ loss at different time points | Baseline through Month 12 and 24 | Mean rate of change in the area of EZ loss (IS/OS; macular photoreceptor loss) from BL through Month 12 (M12) in the study eye(s) and through M12 and M24 in the fellow eye, as assessed using SD-OCT |
| Secondary | Changes in Disease Severity | Baseline through Month 24 | Changes in disease severity (stages, according to Chew et al) in study eye(s), and fellow eye, from BL to M24 |
| Secondary | Retinal Sensitivity Loss | Baseline through Month 24 | Mean change in retinal sensitivity loss as measured by Macular Integrity Assessment (MAIA) from BL to M24 in study eye(s), and fellow eye |
| Secondary | Reading Speed | Baseline through Month 24 | Mean change in monocular and binocular reading speed assessed using International Reading Speed Texts (IReST) cards from BL through M24 in the study eye(s), and fellow eye |
| Secondary | Contrast Sensitivity | Baseline through Month 24 | Mean change in monocular contrast sensitivity from BL to M24 in the study eye(s) and fellow eye as assessed by Pelli-Robson contrast sensitivity charts |
| Secondary | Low Luminance Visual Acuity | Baseline through Month 24 | Mean change in monocular low luminance visual acuity (LLVA) scores from BL to M24 in the study eye(s) and fellow eye as assessed by ETDRS charts |
| Secondary | Low Luminance Deficit | Baseline through Month 24 | Mean change in low luminance deficit (LLVA - BCVA) from BL to M24 in the study eye(s) and fellow eye |
| Secondary | Best Corrected Visual Acuity | Baseline through Month 24 | Mean change in monocular best-corrected visual acuity (BCVA) scores from BL to M24 in the study eye(s) and fellow eye as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) charts |
| Secondary | Corneal Nerve fiber Density | Baseline through Month 6, 12, 18 and 24 | Mean change in corneal nerve fiber and branch density (biomarkers of peripheral nerve health) from BL to M6, M12, M18 and M24 in the study eye(s) and fellow eye |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07342439
GET https://conductscience.org/api/trials/v1/NCT07342439/registered?page=2